Skip To Main Content
Erkan Baloglu on Muck Rack

Erkan Baloglu

As seen in: Nature, The Journal of Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Erkan Baloglu’s profile

Articles by Erkan Baloglu

Author Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

|
By Gabriel Abril-Rodriguez, Davis Y. Torrejon, Wei Liu, Jesse M. Zaretsky, Theodore S Nowicki, Jennifer Tsoi, Cristina Puig-Saus, Egmidio Medina, Alejandro Garcia Verified, Alejandro García Verified, William Senapedis, Erkan Baloglu, Anusha Kalbasi, Gardenia C. Cheung-Lau, Beata Berent-Maoz, Begoña Comin-Anduix, Siwen Hu-Lieskovan, Cun-Yu Wang, Catherine S. Grasso, Antoni Ribas, Ignacio Baselga-Carretero, Michael J. Quist
| Nature Verified
Correction to: Nature Cancer https://doi.org/10.1038/s43018-019-0003-0, published online 9 December 2019. In the version of the article originally published, the legend of Fig. 5 and corresponding source data file did not clarify that in Fig. 5a the n = 16 mice shown per group were pooled from three independent experiments. Fig.
Open in Who Shared Issue with article?

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth

|
By Karyopharm Therapeutics, Erkan Baloglu, Chetan Rane, William Senapedis
| Nature Verified
In this study, we have found that KPT-8752 and KPT-9274 reduce cell proliferation and survival in several triple negative breast cancer cell lines in vitro. The most exciting outcome from this study is that KPT-9274 can inhibit breast cancer tumorigenicity in vivo, in three independent mouse xenograft models using human triple negative breast cancer cell lines.
Open in Who Shared Issue with article?

Pharmacologic Inhibition of RORγt Regulates Th17 Signature Gene Expression and Suppresses Cutaneous Inflammation In Vivo

|
By Jill Skepner, Radha Ramesh, Mark Trocha, Darby Schmidt, Erkan Baloglu
| The Journal of Immunology Verified
IL-17–producing CD4+Th17 cells, CD8+Tc17 cells, and γδ T cells play critical roles in the pathogenesis of autoimmune psoriasis. RORγt is required for the differentiation of Th17 cells and expression of IL-17. In this article, we describe a novel, potent, and selective RORγt inverse agonist (TMP778), and its inactive diastereomer (TMP776). This chemistry, for the first time to our knowledge, provides a unique and powerful set of tools to probe RORγt-dependent functions.
Open in Who Shared Issue with article?
Show More